diversification.com

BPMC

Companies
NASDAQ
Blueprint Medicines Corp.
Health Care
OverviewNewsRisk & CorrelationForecasts
Price Chart
Overview

About BPMC

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Market Cap
$6.5B
Volume
76.1M
Avg. Volume
119.0M
P/E Ratio
-109.57447
Dividend Yield
0.00%
Employees
670.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Latest News for BPMC

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

November 14, 2024

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

June 2, 2025

Sanofi-Blueprint deal is a bullish signal about biotech M&A

June 2, 2025

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

June 2, 2025
Risk & Correlation Analysis
Market Correlation
1.25
High Correlation
Volatility
High (0.48)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for BPMC.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, BPMC shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$6.5B
Volume76.1M
P/E Ratio-109.57
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 1, 2025
Related Securities
IONS
Ionis Pharmaceuticals Inc.
ALKS
Alkermes plc
INCY
Incyte Corporation
VRTX
Vertex Pharmaceuticals Inc.
REGN
Regeneron Pharmaceuticals, Inc.
CARA
Cara Therapeutics Inc.
AMGN
Amgen Inc.

PortfolioPilot Analysis

Get AI-powered insights on how BPMC fits into your investment strategy and portfolio diversification.

Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025